Medical ethics

A domicile rule is preventing an 18-year-old girl from getting a life-saving TB drug

A case that highlights what is wrong with India's national tuberculosis control programme.

A case filed by a father of an 18-year old girl suffering from tuberculosis in the Delhi High Court has exposed the many holes in the government’s tuberculosis control programme.

After suffering from tuberculosis for nearly five years, Priya, whose name has been changed to protect her identity, has now shrunk to 25 kgs. She is barely able to walk a few steps without feeling breathless.

In December 2016, her father had moved the court seeking treatment for his daughter with a drug that the government provides conditional access to. The drug Bedaquiline was incorporated into the Revised National Tuberculosis Control Programme in February 2016 at six hospitals in five cities – Delhi, Mumbai, Chennai, Ahmedabad, and Guwahati. Bedaquiline has shown good results even for patients of extremely drug-resistant tuberculosis for whom all other lines of TB treatment have failed.

Priya has been denied treatment with Bedaquiline, the last form of medication that could save her life, simply because she is not a domicile of Delhi. She is resistant to all the available drugs available for TB so far.

Her father, who is the petitioner has stated that the denial of this treatment is “unconstitutional” and against the current guidelines for treatment with Bedaquiline.

The next date of hearing is on January 9 when the court may decide whether the drug will be made available to her.

Priya’s case highlights the gaping holes in the government’s TB control programme.

When all treatment fails

Priya was first detected with TB in 2011 in Patna. She was only 13 then. Her parents took her to a private doctor who treated her with the first line of TB drugs. Her condition did not improve, with the drugs failing within a few months into the treatment. The family was advised to take her to a government hospital and in 2013, they went to Patna Medical College where Priya was diagnosed with multi drug-resistant tuberculosis.

By November 2014, this treatment regimen also started failing her and the family came to Delhi for the next step. They went to Vallabhbhai Patel Chest Institute in North Campus where Priya was diagnosed as suffering from extremely resistant TB and treatment was started with a third line of drugs. By May 2015, this treatment too became ineffective.

Between 2014 and 2015, Priya had been so sick that she had to be hospitalised several times. She had complained of chest pain, fever and high grade or severe cough for several months.

“In the beginning of a new treatment, she feels better,” said her father, who was in Delhi for the court case. “Within a few months, she would start falling sick. She would start getting weak, would be breathless, and would not feel hungry. It was the same story each time.”

Priya's drug sensitivity test report from November 2014.
Priya's drug sensitivity test report from November 2014.

Unlike the conventional profile of a patient developing drug-resistant tuberculosis because of not following the full course of treatment, Priya appears to have become resistant to even the first line of TB drugs despite not having had treatment before. This is known as primary drug resistance.

“The initial resistance is initial only to the patient,” said Nerges Mistry, director of the Foundation for Medical Research that undertakes research on drug resistant tuberculosis. “But, the bug has seen the drug before.”

Many studies have now shown that even extremely drug-resistant tuberculosis can be transmitted directly from one person to another, Mistry said. In patients like Priya, particularly, it is important to get a profile of the bug to know what medicines could work.

The treatment failure, as Priya – now an avid reader of all issues related to TB – pointed out, is that she was never tested for drug susceptibility properly. “They did not know what medicines worked on me. If they had tested drug susceptibility for all drugs, probably I would be better.”

Priya makes a valid point. Government hospitals do not normally test for the entire profile of drugs that the TB bacilli could be resistant to. Patient groups and activists are asking that the complete profile of the pathogen be tested, as opposed to this limited approach. The treatment can then be tailor-made for a patient.

Clutching at straws

In September 2015, the family took Priya to the National Institute of Tuberculosis and Respiratory Diseases in Delhi, where the physician told her that her TB is incurable and that they should resort to alternate treatment such as homeopathy or ayurveda.

Health activists are shocked by the suggestion. An activist closely associated with the rollout of Bedaquiline in the country said, “What is shocking is that by 2015 the government had already known about Bedaquiline and were even talking of starting a programme here. Why was this girl not told about this drug? Why didn’t they prioritise this girl’s case?”

The family had almost given up hope when they heard of Dr Zarir Udwadia, the chest physician in Hinduja Hospital. Udwadia expressed shock about the doctor’s recommendation of homeopathy or ayurveda and wrote that the prognosis should be “guarded”. He put her on re-purposed drugs that are normally used to treat leprosy and told her family “to try hard” to get Bedaquiline. She was also advised to take Delaminate, a TB drug that is not yet available in India.

In October 2016, Priya tried to get Bedaquiline at the National Institute of Tuberculosis and Respiratory Diseases. Her father said that he knew that he had to be a Delhi resident and was willing to rent a house in Delhi for that purpose. But the doctors told him that Priya cannot avail of the treatment if Priya is not a domicile of the city.

Priya then urged him to file a legal case. Her father asked her, “Will you get better if you file a case?” Priya was adamant. “Many patients do not have the backing I have. What will they do?” she asked.

Drug rollout too slow

Bedaquiline’s rollout in India has been slow and the pace has taken a toll on TB patients who might benefit from the drug, as reported in September 2016.

The reason behind the slow roll out was that the government wanted to be cautious about the drug which had not been tested on Indians yet, explained Indian Council of Medical Research chief Dr Soumya Swaminathan. They wanted the patients to be close to the hospital so that they can be monitored. So far none of the patients has suffered any adverse side effect, she added/

In fact, Bedaquiline is proving to have less side effects as compared to other TB drugs, which have severe known side effects ranging from gastric to psychiatric problems. “Bedaquiline only has the problem of cardiac toxicity, which we now know is not as common,” said Swaminathan.

In an emergency meeting held on December 30, 2016 under directions from the Delhi High Court, a government committee said that Priya needed to undergo another drug-susceptibility test to determine whether she was eligible for Bedaquiline treatment. The committee also said that Priya should continue her treatment with Udwadia, who could procure the drug on the grounds of compassionate use.

Citing compassionate use, a doctor can get the medicine free-of-cost from a drug manufacturer, provided the doctor has convincing evidence that the patients will die without the medicine. This is a commonly-used method of accessing Bedaquline, despite the government stocking the drug for its TB programme.

Committee report on Priya's case.
Committee report on Priya's case.

“The government has abdicated its responsibility,” said Anand Grover, senior counsel appearing for Priya’s father. “It is very conservative and is not willing to part with the drug.”

A new test to prove Priya’s eligibility for Bedaquiline has become problematic. A sputum sample that Priya provided to the National Institute of TB and Respiratory Diseases in October 2016 became contaminated. Since then Priya has become so weak that she has been unable to produce enough sputum for a new sample. In fact, her December samples came out negative for TB on technical grounds.

Dr Jennifer Furin from the Global Health and Social Medicine at Harvard Medical School, in an affidavit submitted to the court on Wednesday, said her previous reports were indicative enough that Priya was eligible for Bedaquiline. Furin also said that the treatment would improve her chances of being cured from less than 50% to more than 80%. Also, the drug would stem the further spread of the disease to people in contact with her.

“The international community has been deeply concerned about the delayed roll out of Bedaquiline in India, the highly limiting enrollment criteria, the strict geographic limitations being placed on patients who need the drug,” Furin stated in her affidavit.

So far, only 164 patients have enrolled for the Bedaquiline programme, while the drugs lying with the government are set to expire in October 2017. Despite this, the government continues to deny treatment to Priya.

In the last hearing on Wednesday, the court has ordered a committee to look into Furin’s affidavit and make a decision on Priya’s treatment by Monday.

“I think we do need to increase the flexibility of the programme,” said Swaminathan. “We have some data and we should be able to go fast now. If the drug is available in the country, every patient should have access.”

We welcome your comments at
Sponsored Content BY 

India’s urban water crisis calls for an integrated approach

We need solutions that address different aspects of the water eco-system and involve the collective participation of citizens and other stake-holders.

According to a UN report, around 1.2 billion people, or almost one fifth of the world’s population, live in areas where water is physically scarce and another 1.6 billion people, or nearly one quarter of the world’s population, face economic water shortage. They lack basic access to water. The criticality of the water situation across the world has in fact given rise to speculations over water wars becoming a distinct possibility in the future. In India the problem is compounded, given the rising population and urbanization. The Asian Development Bank has forecast that by 2030, India will have a water deficit of 50%.

Water challenges in urban India

For urban India, the situation is critical. In 2015, about 377 million Indians lived in urban areas and by 2030, the urban population is expected to rise to 590 million. Already, according to the National Sample Survey, only 47% of urban households have individual water connections and about 40% to 50% of water is reportedly lost in distribution systems due to various reasons. Further, as per the 2011 census, only 32.7% of urban Indian households are connected to a piped sewerage system.

Any comprehensive solution to address the water problem in urban India needs to take into account the specific challenges around water management and distribution:

Pressure on water sources: Rising demand on water means rising pressure on water sources, especially in cities. In a city like Mumbai for example, 3,750 Million Litres per Day (MLD) of water, including water for commercial and industrial use, is available, whereas 4,500 MLD is needed. The primary sources of water for cities like Mumbai are lakes created by dams across rivers near the city. Distributing the available water means providing 386,971 connections to the city’s roughly 13 million residents. When distribution becomes challenging, the workaround is to tap ground water. According to a study by the Centre for Science and Environment, 48% of urban water supply in India comes from ground water. Ground water exploitation for commercial and domestic use in most cities is leading to reduction in ground water level.

Distribution and water loss issues: Distribution challenges, such as water loss due to theft, pilferage, leaky pipes and faulty meter readings, result in unequal and unregulated distribution of water. In New Delhi, for example, water distribution loss was reported to be about 40% as per a study. In Mumbai, where most residents get only 2-5 hours of water supply per day, the non-revenue water loss is about 27% of the overall water supply. This strains the municipal body’s budget and impacts the improvement of distribution infrastructure. Factors such as difficult terrain and legal issues over buildings also affect water supply to many parts. According to a study, only 5% of piped water reaches slum areas in 42 Indian cities, including New Delhi. A 2011 study also found that 95% of households in slum areas in Mumbai’s Kaula Bunder district, in some seasons, use less than the WHO-recommended minimum of 50 litres per capita per day.

Water pollution and contamination: In India, almost 400,000 children die every year of diarrhea, primarily due to contaminated water. According to a 2017 report, 630 million people in the South East Asian countries, including India, use faeces-contaminated drinking water source, becoming susceptible to a range of diseases. Industrial waste is also a major cause for water contamination, particularly antibiotic ingredients released into rivers and soils by pharma companies. A Guardian report talks about pollution from drug companies, particularly those in India and China, resulting in the creation of drug-resistant superbugs. The report cites a study which indicates that by 2050, the total death toll worldwide due to infection by drug resistant bacteria could reach 10 million people.

A holistic approach to tackling water challenges

Addressing these challenges and improving access to clean water for all needs a combination of short-term and medium-term solutions. It also means involving the community and various stakeholders in implementing the solutions. This is the crux of the recommendations put forth by BASF.

The proposed solutions, based on a study of water issues in cities such as Mumbai, take into account different aspects of water management and distribution. Backed by a close understanding of the cost implications, they can make a difference in tackling urban water challenges. These solutions include:

Recycling and harvesting: Raw sewage water which is dumped into oceans damages the coastal eco-system. Instead, this could be used as a cheaper alternative to fresh water for industrial purposes. According to a 2011 World Bank report, 13% of total freshwater withdrawal in India is for industrial use. What’s more, the industrial demand for water is expected to grow at a rate of 4.2% per year till 2025. Much of this demand can be met by recycling and treating sewage water. In Mumbai for example, 3000 MLD of sewage water is released, almost 80% of fresh water availability. This can be purified and utilised for industrial needs. An example of recycled sewage water being used for industrial purpose is the 30 MLD waste water treatment facility at Gandhinagar and Anjar in Gujarat set up by Welspun India Ltd.

Another example is the proposal by Navi Mumbai Municipal Corporation (NMMC) to recycle and reclaim sewage water treated at its existing facilities to meet the secondary purposes of both industries and residential complexes. In fact, residential complexes can similarly recycle and re-use their waste water for secondary purposes such as gardening.

Also, alternative rain water harvesting methods such as harvesting rain water from concrete surfaces using porous concrete can be used to supplement roof-top rain water harvesting, to help replenish ground water.

Community initiatives to supplement regular water supply: Initiatives such as community water storage and decentralised treatment facilities, including elevated water towers or reservoirs and water ATMs, based on a realistic understanding of the costs involved, can help support the city’s water distribution. Water towers or elevated reservoirs with onsite filters can also help optimise the space available for water distribution in congested cities. Water ATMs, which are automated water dispensing units that can be accessed with a smart card or an app, can ensure metered supply of safe water.

Testing and purification: With water contamination being a big challenge, the adoption of affordable and reliable multi-household water filter systems which are electricity free and easy to use can help, to some extent, access to safe drinking water at a domestic level. Also, the use of household water testing kits and the installation of water quality sensors on pipes, that send out alerts on water contamination, can create awareness of water contamination and drive suitable preventive steps.

Public awareness and use of technology: Public awareness campaigns, tax incentives for water conservation and the use of technology interfaces can also go a long way in addressing the water problem. For example, measures such as water credits can be introduced with tax benefits as incentives for efficient use and recycling of water. Similarly, government water apps, like that of the Municipal Corporation of Greater Mumbai, can be used to spread tips on water saving, report leakage or send updates on water quality.

Collaborative approach: Finally, a collaborative approach like the adoption of a public-private partnership model for water projects can help. There are already examples of best practices here. For example, in Netherlands, water companies are incorporated as private companies, with the local and national governments being majority shareholders. Involving citizens through social business models for decentralised water supply, treatment or storage installations like water ATMs, as also the appointment of water guardians who can report on various aspects of water supply and usage can help in efficient water management. Grass-root level organizations could be partnered with for programmes to spread awareness on water safety and conservation.

For BASF, the proposed solutions are an extension of their close engagement with developing water management and water treatment solutions. The products developed specially for waste and drinking water treatment, such as Zetag® ULTRA and Magnafloc® LT, focus on ensuring sustainability, efficiency and cost effectiveness in the water and sludge treatment process.

BASF is also associated with operations of Reliance Industries’ desalination plant at Jamnagar in Gujarat.The thermal plant is designed to deliver up to 170,000 cubic meters of processed water per day. The use of inge® ultrafiltration technologies allows a continuous delivery of pre-filtered water at a consistent high-quality level, while the dosage of the Sokalan® PM 15 I protects the desalination plant from scaling. This combination of BASF’s expertise minimises the energy footprint of the plant and secures water supply independent of the seasonal fluctuations. To know more about BASF’s range of sustainable solutions and innovative chemical products for the water industry, see here.

This article was produced by the Scroll marketing team on behalf of BASF and not by the Scroll editorial team.